For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …

Purpose The development of blood biomarkers that reflect Alzheimer's disease (AD)
pathophysiology (phosphorylated tau and amyloid-β) has offered potential as scalable tests …

There is a great clinical need to identify the underlying mechanisms, as well as related
biomarkers, and treatment targets, for traumatic brain injury (TBI). Neuroinflammation is a …

Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer's disease (AD)
pathology with high accuracy in the general population. In this study, we investigated …

Improved medical care of individuals with Down syndrome (DS) has led to an increase in life
expectancy to over the age of 60 years. In conjunction, there has been an increase in age …

Summary Background Adults with Down syndrome are at an ultra-high risk of Alzheimer's
disease, but diagnosis of Alzheimer's disease in this population is challenging. We aimed to …

Abstract Introduction Neurofilament light chain (NfL) is a promising blood biomarker to detect
neurodegeneration in Alzheimer's disease (AD) and other brain disorders. However, there …

Background Due to trisomy of chromosome 21 and the resultant extra copy of the amyloid
precursor protein gene, nearly all adults with Down syndrome develop Alzheimer's disease …

Introduction Microglial cells play an important role in the development of Alzheimer's
disease (AD). People with Down syndrome (DS) inevitably develop AD neuropathology …

Abstract Introduction People with Down syndrome (DS) are predisposed to Alzheimer's
disease (AD). The amyloid hypothesis informs studies of AD. In AD‐DS, but not sporadic AD …